NOTE FROM TED: This talk only represents the speaker’s personal views and experiences in the military. Some viewers may find elements of this talk alienating or objectionable. We've flagged this talk because it falls outside the content guidelines TED gives TEDx organizers. TEDx events are independently organized by volunteers. The guidelines we give TEDx organizers are described in more detail here: http://storage.ted.com/tedx/manuals/tedx_content_guidelines.pdf In this powerful TEDx talk, Col. Prof. (Dr.) ...

VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that it intends to change its corporate name from “Algernon Health Inc.” to “Grey Matters Health Inc.” (the “Name Change”). The Company has reserved the new name and new symbol “GREY” with the Canadian Securities Exchange (the “CSE”). The new symbols for the OTCQB and Frankfurt exchange will be provided shortl ...

Core Insights - CVS Health's stock closed at $71.82, reflecting a +2.4% change from the previous day, but underperformed compared to the S&P 500's gain of 2.91% [1] - Over the last month, CVS Health shares decreased by 14.11%, while the Medical sector and S&P 500 saw losses of 9.63% and 7.64%, respectively [1] Earnings Performance - CVS Health's upcoming earnings per share (EPS) is projected at $2.2, indicating a 2.22% decrease year-over-year [2] - Revenue is anticipated to be $94.68 billion, showing a slight increase of 0.1% from the same quarter last year [2] Annual Estimates - For the annual period, earnings are expected to be $7.15 per share, with revenue projected at $407.21 billion, reflecting increases of +5.93% and +1.28% year-over-year, respectively [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for CVS Health are crucial as they indicate changing business trends, with upward revisions suggesting analyst optimism about profitability [4] Stock Performance and Zacks Rank - Adjustments in earnings estimates are linked to stock price performance, and CVS Health currently holds a Zacks Rank of 3 (Hold) [5][6] - The Zacks Rank system has a history of outperformance, with 1 stocks averaging +25% annual returns since 1988 [6] Valuation Metrics - CVS Health's Forward P/E ratio is 9.8, which is lower than the industry average of 14.6, indicating a valuation discount [7] - The company has a PEG ratio of 0.73, compared to the Medical Services industry's average PEG ratio of 1.34 [7] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 99, placing it in the top 41% of over 250 industries [8] - Strong industry rankings correlate with better stock performance, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [8]

Company Overview - AirSculpt Technologies, Inc. is an industry leader in premium body contouring procedures, focusing on next-generation treatments that optimize comfort and precision [3]. Financial Results Announcement - AirSculpt will report its fourth quarter and fiscal year 2025 financial results on April 2, 2026, before market open, followed by a conference call at 8:30 a.m. Eastern Time [1]. Conference Call Details - The conference call can be accessed via a toll-free domestic number or an international number, using the conference ID 13758597, and a live webcast will be available on the company's investor relations website [2].

Core Insights - SBC Medical Group Holdings is transitioning from a domestic platform to a globally scalable model, with a focus on the U.S. market and long-term growth strategies [3][4] Financial Performance - Average revenue per visit increased by 11% year-over-year to $316 in Q4, indicating a recovery from previous revenue compression [4] - The company reported a disciplined transition year in 2025, with revenue decline due to structural changes, while net income grew by 9% and margins remained stable [4] Market Positioning - SBC Medical aims to differentiate itself in the fragmented U.S. aesthetic market through a system-driven approach that enhances clinical quality, customer retention, and operational efficiency [3][4] - The company has established a minority investment in OrangeTwist, marking its entry into the U.S. market [4] Business Model - SBC Medical operates a capital-light business model, achieving EBITDA margins above 40% across 283 locations with 6.63 million annual patient visits [4] - The company is focused on long-term growth initiatives, including AI-driven operational infrastructure and expansion into Japan's $34 billion longevity market [4] Strategic Initiatives - The company is actively expanding its global presence, particularly in the U.S. and Asia, through direct operations and medical tourism initiatives [5] - SBC Medical was listed on Nasdaq in September 2024 and included in the Russell 3000® Index in June 2025, enhancing its visibility in the market [5]

Core Viewpoint - Organon (OGN) has experienced a significant decline in stock price and is facing challenges in its upcoming earnings report, with projected decreases in both earnings per share and revenue compared to the previous year [1][2][3]. Company Performance - The stock closed at $5.84, down 3.47% from the previous session, which is less than the S&P 500's loss of 1.67% [1] - Over the past month, Organon's stock has fallen by 16.32%, underperforming the Medical sector's loss of 7.36% and the S&P 500's loss of 6.15% [1]. Earnings Projections - Analysts project earnings per share (EPS) of $0.84 for the upcoming quarter, reflecting a 17.65% decrease from the same quarter last year [2] - Quarterly revenue is expected to be $1.46 billion, down 3.27% from the year-ago period [2]. - For the full year, earnings are projected at $3.37 per share and revenue at $6.16 billion, representing changes of -7.92% and -0.86% respectively from the prior year [3]. Analyst Estimates - Recent changes in analyst estimates for Organon are crucial as they reflect shifting business dynamics, with positive revisions indicating confidence in performance [4]. - The Zacks Rank system, which incorporates these estimate changes, currently ranks Organon at 5 (Strong Sell), with a consensus EPS projection moving 1.72% lower in the past 30 days [6]. Valuation Metrics - Organon is trading with a Forward P/E ratio of 1.79, significantly lower than the industry average Forward P/E of 15.17, indicating a valuation discount [7]. - The company has a PEG ratio of 0.54, compared to the Medical Services industry's average PEG ratio of 1.37 [7]. Industry Context - The Medical Services industry, part of the broader Medical sector, holds a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries [8]. - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [8].

Core Insights - Pediatrix Medical Group, Inc. (MD) has partnered with Tennessee Maternal-Fetal Medicine to enhance its maternal health services, focusing on high-risk pregnancies across five locations in the Greater Nashville area [1][7] - The cash transaction is expected to be immediately accretive to Pediatrix's bottom line, driving higher patient volumes and supporting revenue growth [2][7] - The partnership aims to capture the demand for specialized maternal care, leveraging the expertise of board-certified physicians and practice providers from Tennessee Maternal-Fetal Medicine [3] Financial Performance - Pediatrix's same-unit net revenue increased by 4% year over year in the fourth quarter of 2025, indicating positive growth trends [2] - The stock price of Pediatrix has appreciated by 48.2% over the past year, contrasting with a 6.2% decline in the industry [4] Market Position - Pediatrix currently holds a Zacks Rank of 3 (Hold), while other stocks in the medical sector, such as InnovAge Holding Corp., PACS Group, Inc., and GeneDx Holdings Corp., have higher rankings [5] - The Zacks Consensus Estimate for InnovAge Holding's 2026 earnings is 25 cents per share, with a revenue estimate of $944.5 million, reflecting a 10.6% year-over-year growth [6] - PACS Group's 2026 earnings estimate is $2.09 per share, indicating a 71.3% year-over-year growth, with revenues projected at $5.7 billion, representing a 7.7% increase [8] - GeneDx Holding's 2026 earnings estimate is 75 cents per share, with revenues expected to reach $545 million, implying a 27.5% year-over-year growth [9]

Core Viewpoint - Teladoc Health reported a narrower adjusted loss in Q4 2025 compared to the previous year, driven by international growth and lower costs, but faced challenges from declining U.S. revenues and the BetterHelp segment [3][4][5]. Financial Performance - Q4 2025 adjusted loss was 14 cents per share, better than the expected loss of 19 cents, and an improvement from a loss of 28 cents in the same quarter last year [3]. - Operating revenues for Q4 2025 increased by 0.3% year over year to $642.3 million, surpassing the Zacks Consensus Estimate by 1.3% [3]. - For the full year 2025, operating revenues declined by 1.5% to $2.5 billion, while total expenses fell by 22.2% to $2.8 billion [5]. Segment Performance - Integrated Care segment revenues rose by 5% year over year to $409.1 million, exceeding estimates [9]. - BetterHelp segment revenues decreased by 6% year over year to $229.1 million, missing estimates [10]. - International revenues grew by 19% year over year to $125 million, outperforming expectations [7]. Operational Metrics - Total visits to Teladoc Health were 4.3 million in Q4, down 1% year over year, missing estimates [12]. - U.S. Integrated Care members increased by 9% year over year to 101.8 million, although slightly below consensus [12]. Cash Flow and Balance Sheet - As of December 31, 2025, cash and cash equivalents were $781.1 million, down from $1.3 billion at the end of 2024 [13]. - Net cash from operations for 2025 was $294.4 million, flat year over year, while free cash flow decreased by 2% to $166.9 million [14]. Future Outlook - For Q1 2026, total revenues are expected to be between $598 million and $620 million, with an adjusted EBITDA forecasted between $50 million and $62 million [16]. - For the full year 2026, revenues are projected to be in the range of $2.470 billion to $2.587 billion, with an adjusted EBITDA of $266 million to $308 million [18]. Market Sentiment - Since the earnings release, there has been a downward trend in consensus estimates, with a shift of -9.21% [19]. - Teladoc currently holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [21].

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum [2] Zacks Style Scores Overview - Stocks are rated from A to F based on their value, growth, and momentum characteristics, with A being the highest score [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - The Value Score identifies attractive stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score assesses stocks based on price trends and earnings outlook, utilizing one-week price changes and monthly earnings estimate changes [5] VGM Score - The VGM Score combines all three Style Scores, serving as a comprehensive indicator alongside the Zacks Rank [6] Zacks Rank Integration - The Zacks Rank uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.93% since 1988 [7] - There are typically over 800 top-rated stocks available, making the selection process potentially overwhelming [8] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks but high Style Scores may still carry risks due to downward earnings outlooks [10] Company Spotlight: BrightSpring Health Services, Inc. - BrightSpring Health Services is a national healthcare services platform focusing on home and community-based care for complex patients [11] - The company holds a 1 (Strong Buy) Zacks Rank and a VGM Score of A, with a Momentum Style Score of B and a 6.7% increase in shares over the past four weeks [12] - Analysts have raised earnings estimates for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.21 to $1.61 per share, and an average earnings surprise of +40.4% [12][13]

Core Insights - Aikawa reported a full-year revenue of $174 million, down 15% year-over-year, attributed to business restructuring and fee structure changes [1] - The company ended December 2025 with 283 locations and served 6.63 million customers, with total clinic revenue reaching $1,163 million, representing a 2% year-over-year growth [5] - Despite lower revenue, net income attributable to shareholders increased 9% year-over-year to $51 million, and EPS rose 4% to $0.50 [7] Financial Performance - The company reported EBITDA of $70 million and an EBITDA margin of 40.4%, indicating improved profitability metrics despite a structural transition in revenue [8] - Average revenue per customer increased in the fourth quarter to $316, up 11% year-over-year, signaling a rebound in unit economics [4] Strategic Developments - Management made a strategic investment in OrangeTwist in the U.S. and formed a partnership with BLEZ ASIA in Thailand [1] - The company is focusing on longevity-driven healthcare and AI-driven solutions, with a multi-brand strategy in dermatology to address segmented customer needs [9][13] Domestic Initiatives - Aikawa cited recovery in customer spending and expansion in dermatology, orthopedics, and fertility treatment, establishing the largest AGA hair loss treatment network in Japan [2][14] - The company plans to apply capabilities developed in aesthetic medicine across additional fields, aiming for a number-one position in Japan by 2035 [14] AI and Technology Integration - AI is viewed as a foundational enabler for growth, with applications in automated booking, AI-assisted counseling, and optimization of headquarters functions [15] - The company has hired a CTO with experience in AI call center automation to enhance its technological capabilities [15] M&A and Capital Allocation - Management intends to pursue M&A opportunities that support its goal of becoming number one in targeted fields by 2035, while remaining flexible in capital allocation [16][17] - A previously approved share buyback program is in place to allow for flexible repurchases if market prices fall below appropriate levels [18]